Fresolimumab In Systemic Sclerosis
NCT01284322
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Diffuse Systemic Sclerosis
Interventions
DRUG:
Fresolimumab
Sponsor
Boston University